Plasma levels of tumor necrosis factor superfamily molecules are increased in bipolar disorder by Barbosa, Izabela G. et al.
 DRO  
Deakin Research Online, 
Deakin University’s Research Repository  Deakin University CRICOS Provider Code: 00113B 
Plasma levels of tumor necrosis factor superfamily molecules are increased 
in bipolar disorder 
Citation:  
Barbosa, Izabela G., Neves Vaz, Gabriela, Pessoa Rocha, Natalia, Machado-Vieira, Rodrigo, 
Ventura, Marcio Rogerio Diniz, Huguet, Rodrigo B., Bauer, Moises E., Berk, Michael and 
Teixeira, Antonio L. 2017, Plasma levels of tumor necrosis factor superfamily molecules are 
increased in bipolar disorder, Clinical psychopharmacology and neuroscience, vol. 15, no. 3, 
pp. 269-275. 
 
DOI: http://www.dx.doi.org/10.9758/cpn.2017.15.3.269 
  
 
 
©2018, Korean College of Neuropsychopharmacology 
Reproduced by Deakin University under the terms of the Creative Commons Attribution Non-
Commercial Licence 
 
 
 
 
 
 
Downloaded from DRO: 
http://hdl.handle.net/10536/DRO/DU:30108909 
 
269
Original Article
https://doi.org/10.9758/cpn.2017.15.3.269 pISSN 1738-1088 / eISSN 2093-4327
Clinical Psychopharmacology and Neuroscience 2017;15(3):269-275 Copyrightⓒ 2017, Korean College of Neuropsychopharmacology
                     Received: November 2, 2016 / Revised: January 14, 2017
Accepted: April 9, 2017
Address for correspondence: Izabela G. Barbosa, MD, PhD
Antonio L. Teixeira, MD, PhD
Laboratório Interdisciplinar de Investigação Médica. Faculdade de 
Medicina, UFMG. Av. Alfredo Balena, 190, room 281, Santa 
Efigênia, Belo Horizonte 30130-100, Brazil 
Tel: +55-31-3409-8073
E-mail: izabelagb@gmail.com (Izabela G. Barbosa), 
altexr@gmail.com (Antonio L. Teixeira) 
 This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) 
which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Plasma Levels of Tumor Necrosis Factor Superfamily Molecules Are Increased 
in Bipolar Disorder
Izabela G. Barbosa1, Gabriela Neves Vaz1, Natalia Pessoa Rocha1,2, Rodrigo Machado-Vieira3, 
Marcio Rogerio Diniz Ventura1, Rodrigo B. Huguet1, Moises E. Bauer4, Michael Berk5,6, Antônio L. Teixeira1,2
1Laboratório Interdisciplinar de Investigação Médica, Faculdade de Medicina, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, 
Brazil, 2Neuropsychiatry Program, Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health 
Science Center at Houston, Houston, TX, 3Experimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, Bethesda, 
MD, USA, 4Laboratório de Imunologia do Envelhecimento, Instituto de Pesquisas Biomédicas, Pontifícia Universidade Católica do Rio Grande 
do Sul, Porto Alegre, Brazil, 5Deakin University, IMPACT Strategic Research Centre, School of Medicine, Geelong, 6Orygen, The National Centre  
of Excellence in Youth Mental Health, Department of Psychiatry and The Florey Institute of Neuroscience and Mental Health, The University 
of Melbourne, Parkville, Australia
Objective: Patients with bipolar disorder (BD) exhibit peripheral low-grade inflammation. The aim of the current study was to 
investigate the involvement of hitherto unexplored components of the tumor necrosis factor (TNF) superfamily in BD.
Methods: Eighty patients with type I BD and 50 healthy controls matched for age and gender were enrolled in this study. All 
subjects were assessed with the Mini-Plus to evaluate psychiatric comorbidities; the Young Mania Rating Scale and the Hamilton 
Depression Rating Scale to evaluate manic and depressive symptoms severity, respectively. TNF superfamily molecules (TNF, 
TNF-related weak inducer of apoptosis [TWEAK], TNF-related apoptosis-inducing ligand [TRAIL], soluble TNF receptor type 
1 [sTNFR1], and soluble TNF receptor type 2 [sTNFR2]) levels were measured by ELISA.
Results: Patients with BD, regardless of mood state, presented increased plasma levels of sTNFR1 and TWEAK in comparison 
with controls. 
Conclusion: These findings corroborate the view that TNF superfamily may play a role in BD pathophysiology.
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INTRODUCTION
There is mounting evidence indicating that patients 
with bipolar disorder (BD) present peripheral low-grade 
inflammation. In this regard, one of the most consistently 
reported findings is tumor necrosis factor (TNF)- activa-
tion represented by increased circulating levels of soluble 
TNF receptor type 1 (sTNFR1).1-4) TNF- dysregulation 
was also evidenced in the central nervous system (CNS) of 
patients with BD. A postmortem study found increased 
levels of transmembrane TNF- in the anterior cingulate 
area and decreased levels of TNF- receptor 2 mRNA in 
the dorsolateral prefrontal cortex,5) regions implicated in 
executive functioning.6) Interestingly, we have previously 
shown that impairment in executive functioning was asso-
ciated with increased plasma levels of TNF- and de-
creased plasma levels of soluble TNF receptor type 2 
(sTNFR2) in patients with BD.7)
TNF- is a cytokine that plays a key role in in-
flammatory responses. TNF- acts by regulating the ac-
tivity of immune cells and promoting the secretion of 
pro-inflammatory cytokines. The TNF superfamily in-
cludes several receptors and ligands (most of them in a 
soluble form) that regulate immune responses and apo-
ptosis. Two specific receptors, TNFR1 (p55) and TNFR2 
(p75), bind to TNF- with high affinity, being responsible 
for translating into intracellular pathways TNF- signaling. 
The TNFR1 and TNFR2 transmembrane receptors can be 
cleaved, and the extracellular domains can be released in 
the form of soluble receptors: sTNFR1 and sTNFR2, 
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respectively. Blood levels of these two receptors can vary 
during inflammatory responses. As mentioned above, 
higher circulating levels of sTNFR1 were reported in pa-
tients with BD, especially in mania, in comparison with 
controls.1,8) 
Other components of the TNF superfamily include the 
TNF-related weak inducer of apoptosis (TWEAK) and the 
TNF-related apoptosis-inducing ligand (TRAIL). TWEAK 
attenuates the transition from innate to adaptive T helper 1 
immune response, repressing pro-inflammatory cytokines 
like interferon- and interleukin (IL)-12 produced by nat-
ural killer cells and macrophages, and counterbalancing 
TNF- activity.9,10) TRAIL induces extrinsic apoptotic 
pathway by interacting with its receptors TRAIL-R1 and 
TRAIL-R2, also known as ‘death receptors’.11) Accordingly, 
TRAIL is involved in immune homeostasis and tumor 
suppression.12) TNF-, TRAIL, and TWEAK can also ac-
tivate the NF-kappa B group of transcription factors 
which are implicated in the production of cytokines.13)
There is only one study that evaluated the involvement 
of TWEAK and TRAIL in psychiatric disorders. In this 
study, authors found decreased plasma levels of TWEAK 
in crack cocaine users in comparison with controls. In ad-
dition, TWEAK and TRAIL levels were associated with 
mood symptoms severity.12) Recently, TWEAK was found 
capable to induce depressive symptoms in mice, being im-
plicated on mood disorder pathophysiology.14) 
To date, no study has been conducted in order to eval-
uate the levels of the TNF superfamily molecules TWEAK 
and TRAIL in patients with BD. Therefore, the aim of the 
current study was to investigate the involvement of hither-
to unexplored components of the TNF superfamily in BD. 
We hypothesize that the patients with BD present in-
creased plasma levels of TNF superfamily components in 
comparison with controls. 
METHODS
Eighty patients with type 1 BD and 50 aged-matched con-
trols were enrolled in this study. Patients were consecutively 
recruited from the Mood Disorders Outpatient Clinic at 
Governador Israel Pinheiro Hospital, Belo Horizonte, 
Brazil. BD diagnosis was conﬁrmed independently by two 
psychiatrists according to the Mini-International Neuro-
psychiatric Interview (MINI-Plus).15) Psychiatric co-
morbidities were also evaluated by the MINI-Plus15) inter-
view and were not considered as exclusion criteria. All pa-
tients were assessed by the Young Mania Rating Scale 
(YMRS),16) and the Hamilton Depression Rating Scale 
(HDRS)17) in order to evaluate the severity of manic and 
depressive symptoms, respectively. Remission was deﬁ
ned by YMRS score ＜7 and HDRS score ＜7 points for 
at least eight consecutive weeks. 
Control group was recruited from the local population 
and it was composed of subjects without any psychiatric 
comorbidity, family history of psychiatry disease, suicide 
behavior or cognitive deficit. Controls were subjected to 
MINI-Plus interview to exclude psychiatric disorders. 
Subjects with dementia, infectious or autoimmune dis-
eases, or who had used steroids, anti-inflammatory drugs, 
or antibiotics within four weeks previous to the evaluation 
were excluded from this research protocol. The study was 
approved by the local ethic committees (COEP of Univer-
sidade Federal de Minas Gerais; CAAE.26363614.0. 
0000.5149). All participants signed written informed con-
sent prior to study participation. 
Ten milliliters of blood were drawn by venipuncture in-
to a vacuum tube containing heparin at the same day of the 
clinical assessment (between 8 to 10 a.m.). Blood was im-
mediately centrifuged twice at 1,800 g for 10 minutes. 
Plasma was collected and stored at −70ºC until assayed. 
Plasma levels of TNF- (catalog number: DY210), sTNFR1 
(catalog number: DY225), sTNFR2 (catalog number: 
DY726), TWEAK (catalog number: DY1090), and TRAIL 
(catalog number: DY375) were measured by enzyme- 
linked immunosorbent assay (ELISA) according to the 
procedures supplied by the manufacturer (DuoSet; R&D 
Systems, Minneapolis, MN, USA). All molecules were 
measured in duplicate and experiments were performed 
blinded regarding the participants’ diagnosis. Concentrations 
are expressed as pg/ml.
Descriptive statistics were used to report socio-demo-
graphic and clinical features of the sample. All variables 
were tested for normal distribution by means of the 
Kolmogorov–Smirnov test. Differences between two groups 
(patients vs. controls or BD in remission vs. BD in mania) 
were assessed by Mann–Whitney or Student t tests when 
non-normally or normally distributed, respectively. 
Spearman’s correlation analyses were performed to eval-
uate the association between TWEAK, TRAIL, TNF-, 
sTNFR1, and sTNFR2 levels and age, length of illness, 
YMRS, HDRS scores. All statistical tests were two tailed 
and used a signiﬁcance level of p＜0.05. Statistical analy-
ses were performed using SPSS software version 17.0 
(SPSS Inc., Chicago, IL, USA).
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Table 1. Demographic and clinical features of controls and bipolar 
disorder (BD) patients
Feature Control (n=50) BD patient (n=80) p value
Age (yr) 46.80±9.47 46.09±12.32 0.38*
Sex, male/female 15/35 52/80 0.58
Length of illness (yr) - 22.93±12.66 -
YMRS score - 13.78±13.44 -
HDRS score - 3.70±4.65 -
Medications in use
  Lithium - 43 (53.8) -
  Antipsychotics - 49 (61.3) -
  Anticonvulsants - 39 (48.8) -
Values are presented as mean±standard deviation, number only, 
or number (%). 
YMRS, Young Mania Rating Scale; HDRS, Hamilton Depression Rating 
Scale. 
*Mann Whitney test.
RESULTS
Demographic and clinical features of the study pop-
ulations are shown in Table 1. Control subjects and pa-
tients with BD presented comparable age and gender. 
Among 80 patients with BD, 38 were in remission (11 
male, 27 female; mean±standard deviation [SD] of age 
46.37±11.15 years) and 42 in mania (17 male, 25 female; 
age 51.07±13.02 years). The mean (±SD) length of illness 
was 22.68 (±11.08) years in patients in remission and 
23.19 (±14.26) years in patients in mania. There were no 
significant differences between patients in remission and 
mania regarding age, gender and disease length. Patients 
with BD in mania presented YMRS and HDRS of 25.36 
(±7.48) and 5.09 (±5.49), respectively. Patients with BD 
in remission presented YMRS and HDRS of 1.00 (±1.97) 
and 2.16 (±2.82), respectively. Forty-five out of 80 pa-
tients with BD (56.3%) were in use of at least two different 
mood stabilizer drugs. The information about mood sta-
bilizers in use is shown in Table 1.
We observed changes in plasma levels of TNF family 
molecules in BD. Patients with BD exhibited increased 
plasma levels of sTNFR1 (Fig. 1A) and TWEAK (Fig. 
1C) in comparison with controls. We did not find differ-
ences between patients with BD and controls regarding 
plasma levels of sTNFR2, TRAIL and TNF (Fig. 1A, 1D, 
and 1E, respectively). We found no significant differences 
when comparing the levels of TNF family markers be-
tween patients with BD in remission and in mania (Fig. 
2A-2F). 
In patients with BD, TWEAK plasma levels positively 
correlated with TNF- plasma levels (=0.528, p＜ 
0.001) and with TRAIL plasma levels (=0.621, p＜ 
0.001). TNF-, TRAIL, and TWEAK plasma levels did 
not correlate with age, length of disease, YMRS and 
HDRS scores. TWEAK and TRAIL plasma levels were 
not associated with the presence of psychiatric and clinical 
co-morbidities, nicotine dependence, or the use of any 
mood-stabilizing drug (i.e., atypical antipsychotics, lith-
ium or anticonvulsants). When considering controls, there 
was a positive correlation between TWEAK and Trail 
plasma levels (=0.297, p=0.04).
DISCUSSION
This is the first study to evaluate the TNF superfamily 
molecules TWEAK and TRAIL in BD. Patients with BD 
presented increased plasma levels of TWEAK and 
sTNFR1 in comparison with controls. The changes in 
TWEAK and sTNFR1 levels might be a trait marker of 
BD, since patients in different mood states (i.e., patients in 
mania and patients in remission) did not present any dif-
ference in the levels of the evaluated markers. The current 
results corroborate the view of chronic low-grade in-
flammation in BD, indicating the involvement of the TNF 
superfamily. 
TWEAK plasma levels were increased in BD patients 
regardless their mood state.18) TWEAK has the potential 
to promote tissue remodeling through its ability to orches-
trate inflammatory, angiogenic and/or fibrogenic proc-
esses, and regulate parenchymal cell survival and 
growth.8,10) During acute mood episodes, like mania, in 
parallel with increase in pro-inflammatory stimuli,8,19) 
TWEAK levels may increase in order to control or even 
counterbalance this process. During remission, low grade 
inflammation might also lead to persistent TWEAK path-
way activation. Theoretically, even this mild chronic in-
flammation may drive and/or be associated with pro-
gressive CNS damage and pathological tissue re-
modeling.20,21) It remains to be determined whether 
TWEAK increase is specific for patients with BD or this 
phenomenon is observed in other major psychiatric dis-
eases.
We did not find any significant difference between pa-
tients with BD and controls regarding plasma levels of 
TRAIL. Similar to our study, a previous study involving 
patients with crack cocaine abstinence and controls did 
not report difference in TRAIL plasma levels between 
groups.12) TRAIL is not expressed under physiological 
conditions in the CNS, and its role in regulating in-
flammation and apoptosis in the CNS needs to be further 
explored.22)
TNF- activation is consistently reported in BD. For 
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Fig. 1. Plasma levels of TNF superfamily molecules in patients with bipolar disorder (BD) and controls. Patients with BD presented higher levels 
of sTNFR1 (A) and TWEAK (C) than controls. No differences between groups were observed regarding plasma levels of sTNFR2 (B), TRAIL 
(D), and TNF (E). Plasma levels (pg/ml) of all measured molecules (mean±standard deviation [median]) and statistics are provided in (F). 
TNF, tumor necrosis factor; sTNFR1, soluble TNF receptor type 1; sTNFR2, soluble TNF receptor type 2; TWEAK, TNF-related weak inducer of 
apoptosis; TRAIL, TNF-related apoptosis-inducing ligand.
*Student’s t-test, †Mann-Whitney test. Horizontal bars represent the medians. 
instance, Fiedorowicz et al.23) showed increased circulat-
ing levels of TNF-, as well as its soluble receptors―
sTNFR1/sTNFR2―in mania. Similarly, Pandey et al.24) 
described high mRNA levels of TNF-, TNFR1 and 
IL-1R1 in BD. TNF- degrades soon after release, partly 
explaining the fact that this molecule is not necessarily 
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Fig. 2. Plasma levels of TNF superfamily molecules in patients with bipolar disorder (BD) in remission and in mania. Patients with BD in remission 
and in mania presented similar plasma levels of sTNFR1 (A), sTNFR2 (B), TWEAK (C), TRAIL (D), and TNF (E). Plasma levels (pg/ml) of all 
measured molecules (mean±standard deviation [median]) and statistics are provided in (F). 
TNF, tumor necrosis factor; sTNFR1, soluble TNF receptor type 1; sTNFR2, soluble TNF receptor type 2; TWEAK, TNF-related weak inducer of 
apoptosis; TRAIL, TNF-related apoptosis-inducing ligand.
*Student’s t-test, †Mann-Whitney test. Horizontal bars represent the medians.
found altered in BD case series.8) It is worth mentioning 
that inconsistencies in the literature might also arise from 
the heterogeneity of BD samples in terms of clinical fea-
tures and immune profile. Anyway, TNF- levels pos-
itively correlated with TWEAK and our results reinforce 
the hypothesis that the TNF system is activated in BD.
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This study has strengths and limitations that must be 
considered when interpreting the results. The diagnostic 
interviews of patients and controls were performed using 
the same protocol. In addition, the exclusion of patients 
with medical conditions such as inflammatory diseases 
can be regarded as strength of the study. The lack of strict 
control for confounding factors, such as body mass index, 
medications in use, and tobacco use must be considered 
limitations, as well as the cross-sectional nature of the 
study. In-vitro studies have demonstrated that mood sta-
bilizers, antipsychotics, and antiepileptic drugs influence 
the production of inflammatory markers by immune 
cells.25,26) Our results, however, were not influenced by 
medication in use. In addition, it would have been in-
formative to evaluate the association between function-
ality and the TNF molecules’ levels and to have a bipolar 
depression only arm as well. The fact that other molecules 
from the TNF superfamily were not investigated is also a 
limitation of our study. 
In conclusion, our findings reinforce the view that in-
flammatory dysfunction is present in BD and that the TNF 
superfamily, particularly TWEAK, may play a role in the 
pathophysiology of BD. Given the role of TWEAK as an 
apoptosis regulator, this study has implications for the un-
derstanding the pathways to progressive CNS structural 
changes in BD. 
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